{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,2]],"date-time":"2026-04-02T20:22:44Z","timestamp":1775161364900,"version":"3.50.1"},"reference-count":40,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2014,7,1]],"date-time":"2014-07-01T00:00:00Z","timestamp":1404172800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["jocn-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Clinical Neuroscience"],"published-print":{"date-parts":[[2014,7]]},"DOI":"10.1016\/j.jocn.2013.06.029","type":"journal-article","created":{"date-parts":[[2013,12,10]],"date-time":"2013-12-10T04:15:30Z","timestamp":1386648930000},"page":"1180-1187","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["Managing tuberous sclerosis in the Asia-Pacific region: Refining practice and the role of targeted therapy"],"prefix":"10.1016","volume":"21","author":[{"given":"John A.","family":"Lawson","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chi-Fung","family":"Chan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ching-Shiang","family":"Chi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pi-Chuan","family":"Fan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Heung Dong","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ki Joong","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Surachai","family":"Likasitwatanakul","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marilyn","family":"Ortiz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kate","family":"Riney","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stacey Kiat-Hong","family":"Tay","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chee-Kian","family":"Tham","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jocn.2013.06.029_b0005","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1038\/sj.ejhg.5201625","article-title":"Tuberous sclerosis","volume":"14","author":"Yates","year":"2006","journal-title":"Eur J Hum Genet"},{"key":"10.1016\/j.jocn.2013.06.029_b0010","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.jaad.2007.05.004","article-title":"Tuberous sclerosis complex: advances in diagnosis, genetics, and management","volume":"57","author":"Schwartz","year":"2007","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jocn.2013.06.029_b0015","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1111\/j.1749-6632.2009.05117.x","article-title":"The tuberous sclerosis complex","volume":"1184","author":"Orlova","year":"2010","journal-title":"Ann N Y Acad Sci"},{"key":"10.1016\/j.jocn.2013.06.029_b0020","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1111\/j.1528-1167.2009.02341.x","article-title":"Mammalian target of rapamycin (mTOR) inhibition as a potential antiepileptogenic therapy: from tuberous sclerosis to common acquired epilepsies","volume":"51","author":"Wong","year":"2010","journal-title":"Epilepsia"},{"key":"10.1016\/j.jocn.2013.06.029_b0025","doi-asserted-by":"crossref","first-page":"1801","DOI":"10.1056\/NEJMoa1001671","article-title":"Everolimus for subpendymal giant-cell astrocytomas in tuberous sclerosis","volume":"363","author":"Krueger","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jocn.2013.06.029_b0030","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1586\/era.11.93","article-title":"Everolimus: an mTOR inhibitor for the treatment of tuberous sclerosis","volume":"11","author":"Franz","year":"2011","journal-title":"Expert Rev Anticancer Ther"},{"key":"10.1016\/j.jocn.2013.06.029_b0035","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1056\/NEJMra055323","article-title":"The tuberous sclerosis complex","volume":"355","author":"Crino","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jocn.2013.06.029_b0040","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1186\/1471-2350-7-72","article-title":"Molecular and clinical analyses of 84 patients with tuberous sclerosis complex","volume":"7","author":"Huang","year":"2006","journal-title":"BMC Med Genet"},{"key":"10.1016\/j.jocn.2013.06.029_b0045","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1086\/316951","article-title":"Mutational analysis in a cohort of 224 tuberous sclerosis patients indicates increased severity of TSC2, compared with TSC1, disease in multiple organs","volume":"68","author":"Dabora","year":"2001","journal-title":"Am J Hum Genet"},{"key":"10.1016\/j.jocn.2013.06.029_b0050","doi-asserted-by":"crossref","first-page":"e117","DOI":"10.1542\/peds.2010-0192","article-title":"Tuberous sclerosis complex: diagnostic challenges, presenting symptoms, and commonly missed signs","volume":"127","author":"Staley","year":"2011","journal-title":"Pediatrics"},{"key":"10.1016\/j.jocn.2013.06.029_b0055","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1016\/j.ejpn.2011.03.010","article-title":"Antiepileptic treatment before the onset of seizures reduces epilepsy severity and risk of mental retardation in infants with tuberous sclerosis complex","volume":"15","author":"J\u00f3\u017awiak","year":"2011","journal-title":"Eur J Paediatr Neurol"},{"key":"10.1016\/j.jocn.2013.06.029_b0060","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1016\/S0140-6736(08)61279-9","article-title":"Tuberous sclerosis","volume":"372","author":"Curatolo","year":"2008","journal-title":"Lancet"},{"key":"10.1016\/j.jocn.2013.06.029_b0065","doi-asserted-by":"crossref","first-page":"1571","DOI":"10.1185\/03007995.2011.586687","article-title":"Burden of disease and unmet needs in tuberous sclerosis complex with neurological manifestations: a systematic review","volume":"27","author":"Hallett","year":"2011","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.jocn.2013.06.029_b0070","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1177\/088307389801301206","article-title":"Tuberous sclerosis complex consensus conference: revised clinical diagnostic criteria","volume":"13","author":"Roach","year":"1998","journal-title":"J Child Neurol"},{"key":"10.1016\/j.jocn.2013.06.029_b0075","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1159\/000254570","article-title":"Tuberous sclerosis: epidemiology, genetics and progress towards treatment","volume":"33","author":"Morrison","year":"2009","journal-title":"Neuroepidemiology"},{"key":"10.1016\/j.jocn.2013.06.029_b0080","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1177\/088307389901400610","article-title":"Tuberous sclerosis consensus conference: recommendations for diagnostic evaluation. National tuberous sclerosis association","volume":"14","author":"Roach","year":"1999","journal-title":"J Child Neurol"},{"key":"10.1016\/j.jocn.2013.06.029_b0085","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1111\/j.1440-1754.2011.02038.x","article-title":"An Australian tuberous sclerosis cohort: are surveillance guidelines being met?","volume":"47","author":"Chopra","year":"2011","journal-title":"J Paediatr Child Health"},{"key":"10.1016\/j.jocn.2013.06.029_b0090","doi-asserted-by":"crossref","first-page":"1236","DOI":"10.1111\/j.1528-1167.2009.02474.x","article-title":"The natural history of epilepsy in tuberous sclerosis complex","volume":"51","author":"Chu-Shore","year":"2010","journal-title":"Epilepsia"},{"key":"10.1016\/j.jocn.2013.06.029_b0095","article-title":"Tuberous sclerosis complex","author":"Northrup","year":"1993"},{"key":"10.1016\/j.jocn.2013.06.029_b0100","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1111\/j.1528-1167.2007.01117.x","article-title":"Epilepsy surgery in tuberous sclerosis: a systematic review","volume":"48","author":"Jansen","year":"2007","journal-title":"Epilepsia"},{"key":"10.1016\/j.jocn.2013.06.029_b0105","doi-asserted-by":"crossref","first-page":"381","DOI":"10.3171\/2010.7.PEDS10221","article-title":"Rapamycin as an alternative to surgical treatment of subependymal giant cell astrocytomas in a patient with tuberous sclerosis complex","volume":"6","author":"Birca","year":"2010","journal-title":"J Neurosurg Pediatr"},{"key":"10.1016\/j.jocn.2013.06.029_b0110","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1183\/09031936.06.00113303","article-title":"Lymphangioleiomyomatosis","volume":"27","author":"Johnson","year":"2006","journal-title":"Eur Respir J"},{"key":"10.1016\/j.jocn.2013.06.029_b0115","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1038\/369756a0","article-title":"A mammalian protein targeted by G1-arresting rapamycin-receptor complex","volume":"369","author":"Brown","year":"1994","journal-title":"Nature"},{"key":"10.1016\/j.jocn.2013.06.029_b0120","doi-asserted-by":"crossref","first-page":"27582","DOI":"10.1074\/jbc.272.44.27582","article-title":"FKBP12 binds the inositol 1,4,5-trisphosphate receptor at leucine-proline (1400\u20131401) and anchors calcineurin to this FK506-like domain","volume":"272","author":"Cameron","year":"1997","journal-title":"J Biol Chem"},{"key":"10.1016\/j.jocn.2013.06.029_b0125","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1128\/MMBR.66.4.579-591.2002","article-title":"Elucidating TOR signaling and rapamycin action: lessons from Saccharomyces cerevisiae","volume":"66","author":"Crespo","year":"2002","journal-title":"Microbiol Mol Biol Rev"},{"key":"10.1016\/j.jocn.2013.06.029_b0130","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1016\/j.cell.2006.01.016","article-title":"TOR signaling in growth and metabolism","volume":"124","author":"Wullschleger","year":"2006","journal-title":"Cell"},{"key":"10.1016\/j.jocn.2013.06.029_b0135","doi-asserted-by":"crossref","first-page":"S169","DOI":"10.4161\/cbt.365","article-title":"The molecular target of rapamycin (mTOR) as a therapeutic target against cancer","volume":"2","author":"Mita","year":"2003","journal-title":"Cancer Biol Ther"},{"key":"10.1016\/j.jocn.2013.06.029_b0140","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1186\/1756-8722-2-45","article-title":"Targeting tumorigenesis: development and use of mTOR inhibitors in cancer therapy","volume":"2","author":"Yuan","year":"2009","journal-title":"J Hematol Oncol"},{"key":"10.1016\/j.jocn.2013.06.029_b0145","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1002\/ana.20784","article-title":"Rapamycin causes regression of astrocytomas in tuberous sclerosis complex","volume":"59","author":"Franz","year":"2006","journal-title":"Ann Neurol"},{"key":"10.1016\/j.jocn.2013.06.029_b0150","doi-asserted-by":"crossref","first-page":"e23379","DOI":"10.1371\/journal.pone.0023379","article-title":"Multicenter phase 2 trial of sirolimus for tuberous sclerosis: kidney angiomyolipomas and other tumors regress and VEGF-D levels decrease","volume":"6","author":"Dabora","year":"2011","journal-title":"PLoS ONE"},{"key":"10.1016\/j.jocn.2013.06.029_b0155","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1056\/NEJMc072500","article-title":"Sirolimus therapy in tuberous sclerosis or sporadic lymphangioleiomyomatosis","volume":"358","author":"Davies","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jocn.2013.06.029_b0160","doi-asserted-by":"crossref","first-page":"121","DOI":"10.2165\/11634580-000000000-00000","article-title":"Topical rapamycin therapy to alleviate the cutaneous manifestations of tuberous sclerosis complex: a double-blind, randomized, controlled trial to evaluate the safety and efficacy of topically applied rapamycin","volume":"12","author":"Koenig","year":"2012","journal-title":"Drugs R D"},{"key":"10.1016\/j.jocn.2013.06.029_b0165","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1111\/j.1440-0960.2011.00837.x","article-title":"Topical 0.1% rapamycin for angiofibromas in paediatric patients with tuberous sclerosis: a pilot study of four patients","volume":"53","author":"Foster","year":"2012","journal-title":"Australas J Dermatol"},{"key":"10.1016\/j.jocn.2013.06.029_b0170","unstructured":"Novartis Pharmaceuticals Corporation. AFINITOR (everolimus) tablets for oral administration: full prescribing information. East Hanover, NJ, USA: Novartis; 2012. [updated 2012; cited June 2012]. Available from: www.pharma.us.novartis.com\/product\/pi\/pdf\/afinitor.pdf."},{"key":"10.1016\/j.jocn.2013.06.029_b0175","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1212\/WNL.0b013e318247ca8d","article-title":"Everolimus alters white matter diffusion in tuberous sclerosis complex","volume":"78","author":"Tillema","year":"2012","journal-title":"Neurology"},{"key":"10.1016\/j.jocn.2013.06.029_b0180","first-page":"11","article-title":"Long-term safety and efficacy of oral everolimus in the treatment of patients with subependymal giant cell astrocytomas in tuberous sclerosis complex: results from an open-label, extension phase of a prospective, phase I\u2013II study","volume":"52","author":"Krueger","year":"2011","journal-title":"Epilepsia"},{"key":"10.1016\/j.jocn.2013.06.029_b0185","doi-asserted-by":"crossref","first-page":"51","DOI":"10.2165\/11207730-000000000-00000","article-title":"Everolimus in patients with subependymal giant cell astrocytoma associated with tuberous sclerosis complex","volume":"14","author":"Curran","year":"2012","journal-title":"Pediatr Drugs"},{"key":"10.1016\/j.jocn.2013.06.029_b0190","doi-asserted-by":"crossref","first-page":"P04.18","DOI":"10.1212\/WNL.78.1_MeetingAbstracts.P04.188","article-title":"Everolimus for the treatment of angiomyolipoma in patients with tuberous sclerosis complex or sporadic lymphangioleiomyomatosis: results from EXIST-2 (P04.188)","volume":"78","author":"Frost","year":"2012","journal-title":"Neurology"},{"key":"10.1016\/j.jocn.2013.06.029_b0195","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1159\/000254569","article-title":"Prevalence of tuberous sclerosis complex in Taiwan: a national population-based study","volume":"33","author":"Hong","year":"2009","journal-title":"Neuroepidemiology"},{"key":"10.1016\/j.jocn.2013.06.029_b0205","first-page":"6","article-title":"Unlocking a cure for tuberous sclerosis complex: an assessment of scientific progress and research needs","volume":"126","author":"Whittemore","year":"2012","journal-title":"Perspective"}],"container-title":["Journal of Clinical Neuroscience"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0967586813006462?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0967586813006462?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,8,4]],"date-time":"2019-08-04T18:45:43Z","timestamp":1564944343000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0967586813006462"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,7]]},"references-count":40,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2014,7]]}},"alternative-id":["S0967586813006462"],"URL":"https:\/\/doi.org\/10.1016\/j.jocn.2013.06.029","relation":{},"ISSN":["0967-5868"],"issn-type":[{"value":"0967-5868","type":"print"}],"subject":[],"published":{"date-parts":[[2014,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Managing tuberous sclerosis in the Asia-Pacific region: Refining practice and the role of targeted therapy","name":"articletitle","label":"Article Title"},{"value":"Journal of Clinical Neuroscience","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jocn.2013.06.029","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2013 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}